S.G. Power Limited is embarking on a significant corporate transformation, moving away from its traditional roots to establish a strong foothold in the healthcare and pharmaceutical industry. Following a strategic decision by its board of directors, the company aims to reposition itself as a healthcare-centric entity, focusing initially on pharmaceutical licensing, distribution, and trading. This pivot is designed to tap into the high-growth potential of the healthcare sector, which is known for its resilience and consistent demand. By shifting its focus, S.G. Power intends to create a scalable platform that can generate immediate revenue while providing a foundation for long-term expansion within the broader medical ecosystem.
To facilitate this transition, the company is undergoing a comprehensive legal and structural overhaul. According to a recent filing with the Pakistan Stock Exchange, S.G. Power will amend its Memorandum and Articles of Association to formally include operations related to pharmaceuticals and allied healthcare sectors. As part of this rebranding effort, the company will also change its name to better reflect its new business direction and market identity. Furthermore, the firm has decided to relocate its registered office from Sindh to Punjab, a move intended to align its legal and administrative base with its new operational focus and geographical priorities.
Financial readiness is a key component of this ambitious plan. The company’s board has approved an increase in authorized share capital to 800 million. This capital injection is intended to support upcoming fundraising initiatives and provide the necessary working capital to kickstart its pharmaceutical operations. The entry strategy focuses on a distribution-led model, which allows for a rapid market entry with relatively low capital intensity. This approach is designed to ensure that the company becomes revenue-generating in the near term while it works on securing long-term growth through more complex pharmaceutical ventures.
Compliance and regulatory adherence are at the forefront of this shift. S.G. Power is set to begin the formal process of obtaining the necessary approvals from the Drug Regulatory Authority of Pakistan. These licenses are essential for the company to legally participate in the pharmaceutical supply chain. While these regulatory steps are underway, the board has also authorized the creation of both domestic and international subsidiaries, as well as special purpose vehicles. These structures will enable the company to pursue strategic partnerships, joint ventures, and distribution agreements with both local and international pharmaceutical operators, broadening its reach and expertise.
The execution of this transformation is on a fast track, with a targeted timeline of 90 to 120 days. Once completed, S.G. Power expects to emerge as an active participant in the healthcare market, with a significantly enhanced earnings profile and a modernized market position. To finalize these changes, the company will convene an extraordinary general meeting to seek formal approval from its shareholders for the restructuring, capital increases, and new strategic initiatives. This bold move represents a total reimagining of the company’s future, moving from power generation into the vital and expanding field of national healthcare.
Follow the PakBanker Whatsapp Channel for updates across Pakistan’s banking ecosystem